KBroVet-CA1 (potassium bromide chewable tablets) for Dogs

Anti seizure potassium bromide support for dogs

Product Description

KBroVet CA1 is a flavored potassium bromide chewable tablet created to help control seizures caused by idiopathic epilepsy in dogs. It offers steady oral dosing that supports long term seizure management under veterinary supervision. The tablets are prescription only and suitable for daily use as part of a personalized treatment plan.

Benefits

• Epilepsy support: Works to lessen both the number of seizures and their strength in dogs with idiopathic epilepsy.
• Long term stability: Offers controlled daily dosing that supports sustained serum bromide levels for ongoing neurological steadiness.
• Flexible dosing option: Can be given with or without food and may follow a loading plan when needed for certain dogs.
• Veterinary guided safety: Designed for monitored use to maintain safe electrolyte balance and reduce risks linked to bromide therapy.
• Flavor designed tablets: Flavored chewables help improve acceptance and simplify daily administration for dogs.

Variants

• 250 mg Chewable Tablets 60 count
• 250 mg Chewable Tablets 180 count
• 500 mg Chewable Tablets 60 count
• 500 mg Chewable Tablets 180 count

Ingredients

Active Ingredient

Potassium bromide

How to Use

Dosage & Administration Instructions

• Daily dosing guidance: Administer the total daily potassium bromide amount once per day while monitoring your dog's clinical response.
• Food flexibility: Give the chewable tablet with or without food, based on what works best for your dog.
• Loading dose consideration: A loading regimen may be used when faster therapeutic results are needed under veterinary direction.
• Monitor clinical signs: Observe your dog closely for changes in appetite, coordination, or water intake during treatment.
• Diet stability needed: Keep dietary chloride levels steady to help maintain consistent serum bromide concentrations.
• Use caution with fluids: Use care when administering chloride-containing IV fluids, as they can lower serum bromide levels.
• Adjustments by veterinarian: Any dose changes should be made only by a veterinarian after assessing seizure control and safety.
• Weight-based dosing: Provide a daily dose that falls between 25 and 68 mg per kg of your dog’s weight.

Additional Information

Precautions

• Diet consistency: Keep your dog’s diet steady because changes in chloride intake can quickly alter bromide blood levels.
• Monitor electrolytes: Dogs with electrolyte balance issues require careful monitoring during potassium bromide therapy.
• Renal concerns: Dogs with impaired kidney function may accumulate bromide faster and face an increased risk of toxicity.
• Drug interactions: Use caution when adding other medications since some can influence how bromide works inside the body.
• Not for young dogs: Safety in puppies, breeding dogs, pregnant dogs, or nursing dogs has not been established.
• Not for every case: Some dogs may not respond fully to potassium bromide alone and may require additional antiepileptic support.

Possible Side Effects

• Increased appetite: Some dogs show noticeably higher hunger levels early in treatment or during steady state dosing.
• Weight gain: Dogs may gain weight over time due to appetite changes and metabolic response to therapy.
• Vomiting episodes: Occasional vomiting or regurgitation can occur, especially during initial treatment periods.
• Sedation signs: Mild to moderate sleepiness or reduced energy may appear during the adjustment phase.
• Coordination issues: Ataxia or an unsteady gait may develop, especially when bromide levels become elevated.
• Increased thirst: Some dogs experience heightened water intake and may drink more than usual.
• Urination changes: Increased urination may accompany the rise in drinking habits during treatment.

Storage Information

• Controlled temperature storage: Make sure the tablets are kept indoors at a stable temperature of 20 to 25 degrees Celsius.
• Keep sealed: Keep the container securely closed to protect the tablets and maintain product stability.
• Pet safe location: Store the bottle in a place that pets cannot reach to prevent accidental ingestion or overdose.
• Child safe placement: Keep out of reach of children since accidental ingestion requires immediate medical attention.

Shipping & Return

We offer ground, express, priority, and international delivery; see our shipping policy for details.

For return instructions or product concerns, please refer to our detailed refund policy. 

Prescription items are NON-RETURNABLE and NON-REFUNDABLE. 

Frequently Asked Questions

Q1: How does KBroVet CA1 help manage seizures in dogs

Ans: KBroVet CA1 uses potassium bromide to stabilize neuronal activity by passing through chloride channels. This raises the seizure threshold and reduces seizure spread in dogs with idiopathic epilepsy. Its effectiveness is supported by retrospective clinical evaluations in treated dogs.

Q2: How long does it take for potassium bromide to reach steady state levels

Ans: Potassium bromide has a long elimination half life, and steady state levels typically develop after several weeks of consistent dosing. Some studies observed steady state around day 115 depending on dose, frequency, and individual metabolism.

Q3: Can KBroVet CA1 be given with food

Ans: Yes, KBroVet CA1 can be given with or without food. Some dogs may handle it better with food, since eating first can help lessen stomach upset according to reported safety observations.

Q4: What side effects should I watch for while my dog is taking potassium bromide

Ans: Common reactions include increased appetite, weight gain, sedation, vomiting, increased thirst, and ataxia. These signs occurred in retrospective studies evaluating dogs treated with potassium bromide for seizure control. Veterinary monitoring is recommended during treatment.

Q5: Can KBroVet CA1 be used with other seizure medications

Ans: It can be used with veterinary guidance, but adverse effects increase when combined with medicines like phenobarbital. Neurologic signs such as sedation, behavioral changes, ataxia, and hind limb weakness have been reported during combination therapy.